A network meta-analysis of the efficacy and safety of baloxavir marboxil versus neuraminidase inhibitors for the treatment of influenza in otherwise healthy patients

CMRO - Baloxavir demonstrated better or similar efficacy results compared to other antivirals used in the treatment of influenza with a comparable safety profile. Baloxavir led to a significant decrease in viral titer versus zanamivir, oseltamivir and peramivir and decreased viral shedding versus zanamivir and oseltamivir. Read More →

Read More
Brea Neri
FDA Approves Liquid Colchicine Formulation for Gout

FDA - Colchicine oral solution 0.6 mg/5 mL (GLOPERBA) has become the first liquid formulation of the therapy approved by the FDA for the preventive treatment of gout flares. The new liquid, oral formulation allows physicians to make simpler dosage adjustments for their patients than current capsule and tablet formulations. Additionally, the approved therapy may be particularly benefit to the estimated 15% of elderly patients who have difficulty swallowing capsule or tablet drugs. Read More →

Read More
Brea Neri
Disclosure of complementary medicine use to medical providers: a systematic review and meta-analysis

Scientific Reports - Concomitant complementary medicine (CM) and conventional medicine use is frequent and carries potential risks. Yet, CM users frequently neglect to disclose CM use to medical providers. Meta-analysis revealed a 33% disclosure rate with reasons for non-disclosure including lack of inquiry from medical providers, fear of provider disapproval, perception of disclosure as unimportant, belief providers lacked CM knowledge, lacking time, and belief CM was safe. Read More →

Read More
Brea Neri
New York Times: The Case Against Cough Medicine

Coughs are one of the leading reasons for visits to the doctor and trips to the drugstore, yet evidence is sorely lacking for the value of any over-the-counter remedy to treat most coughs, be they wet or dry. They are also not totally free of side effects and the American Academy of Pediatrics says there’s no reason to use them in children under 6. Read More →

Read More
Brea Neri
Safety trial finds risk of blood clots in the lungs and death with higher dose of tofacitinib (Xeljanz, Xeljanz XR) in rheumatoid arthritis patients; FDA to investigate

FDA – alerting the public that a safety clinical trial found an increased risk of blood clots in the lungs (pulmonary embolism) and death when a 10 mg twice daily dose of tofacitinib (Xeljanz, Xeljanz XR) was used in patients with rheumatoid arthritis (RA). The FDA has not approved this 10 mg twice daily dose for RA; this dose is only approved in the dosing regimen for patients with ulcerative colitis. Read More →

Read More
Brea Neri
Survey: Patients concerned about taking medication properly

More than half of patients lack confidence in their ability to properly take new medications as directed with two-thirds of patients blaming their anxiety on a lack of time with physicians at the point of care. Survey respondents found that the least preferred format for educational information on medications is written materials while they would most prefer learning about a drug’s purpose and potential side effects from a short online video sent by their doctor or pharmacist via a link. Read More →

Read More
Brea Neri
2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation

AHA/ACC/HRS – released an update to their 2014 Guideline for the Management of Patients with Atrial Fibrillation. Additions included recommending NOACs (dabigatran, rivaroxaban, apixaban, and edoxaban) over warfarin in NOAC-eligible patients with AF (except with moderate-to-severe mitral stenosis or a mechanical heart valve) and recommending weight loss combined with risk factor modification in overweight or obese patients with AF. Read More →

Read More
Brea Neri
FDA approves first generic Advair Diskus

FDA - approved the first generic of Advair Diskus (fluticasone propionate and salmeterol inhalation powder) for the twice-daily treatment of asthma in patients aged four years and older and maintenance treatment of airflow obstruction and reducing exacerbations in patients with COPD. Read More →

Read More
Brea Neri
Dr. Reddy’s Laboratories and Its U.S. Subsidiary, Promius Pharma, Announce FDA Approval for TOSYMRA™ (Sumatriptan Nasal Spray) 10 mg, in the U.S. Market

FDA approved TOSYMRA which is indicated for the acute treatment of migraine with or without aura in adults. TOSYMRA nasal spray is formulated using a proprietary novel excipient known as Intravail® to achieve blood levels similar to a 4-mg sumatriptan subcutaneous injection, resulting in rapid onset of action. Read More →

Read More
Brea Neri
FDA approves use of 0.5 mL dose of Fluzone® Quadrivalent (influenza vaccine) in children as young as 6 months of age

FDA - approved the use of the 0.5 mL dose of Fluzone® Quadrivalent (influenza vaccine) to include children age 6 through 35 months. Sanofi Pasteur, the vaccine division of Sanofi, will have the 0.5 mL dose, in addition to the 0.25 mL dose, available for the upcoming 2019-20 season for this expanded age range. This new option offers health care providers the convenience of using the same 0.5 mL dose for all eligible children when immunizing against the flu. Read More →

Read More
Brea Neri
Benzodiazepines or related drugs and risk of pneumonia: A systematic review and meta‐analysis

Geriatric Psychiatry - Current or recent exposure (within 30-90 days) to benzodiazepines and related drugs (BZRDs), including zolpidem, is associated with an 1.25-fold increased pneumonia risk. Older patients and those taking short- or intermediate-acting BZRDs were at greater risk. Clinicians need to weigh the benefit‐risk balance of BZRD use, especially in those with other risk factors for pneumonia. Read More →

Read More
Brea Neri
JAMA: Evaluation and Management of Penicillin Allergy

JAMA - Approximately 10% of the US population has reported allergies to the β-lactam agent penicillin, however, clinically significant IgE-mediated or T lymphocyte–mediated penicillin hypersensitivity is uncommon (<5%). This results in the use of broad-spectrum antibiotics that increase the risk for antimicrobial resistance and adverse events. Direct amoxicillin challenge is appropriate for patients with low-risk allergy histories and moderate-risk patients can be evaluated with penicillin skin testing. Read More →

Read More
Brea Neri